BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 18, 2026
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» PPMD funding supports Kinea’s AAV-mediated midi-dystrophin gene replacement therapy for DMD
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
PPMD funding supports Kinea’s AAV-mediated midi-dystrophin gene replacement therapy for DMD
Feb. 14, 2024
Parents Project Muscular Dystrophy (PPMD) has provided $500,000 in funding to Kinea Bio Inc.
BioWorld Science
Gene therapy
Neurology/psychiatric
Grant